

## VACCINE EXCHANGE – PRODUCT DEVELOPMENT WORKSHOP

23 November 2018 – Flinders University, Bedford Park, Adelaide  
Lecture Theatre 4, 5<sup>th</sup> Floor, Flinders Medical Centre  
9am start – 5pm Finish  
Lunch Provided  
Free Registration – Limited Numbers

A range of real life vaccine case studies will be discussed

### Key Speakers are



**Meera Verma**, PhD, FTSE, FAICD, is a professional executive with expertise spanning the global healthcare, biotechnology and renewable energy industries. She is the Principal of Headland Vision, a strategic product development advisory and consultancy. She recently served in an interim role as Executive Director at Ellex Medical, a specialist global ophthalmic laser company. And prior to that was Acting CEO of TechInSA, which is the SA Government's business catalyst, focused on fast-tracking the high-tech industry, bringing innovative South Australian products and technologies to global markets. She previously served as Site Director for the Adelaide-based R&D and manufacturing facility of Hospira Inc., a Chicago-based global specialty pharmaceutical and Medication Company, now a division of the global giant Pfizer. Dr. Verma is a Fellow of both the Australian Academy of Technological Sciences and Engineering (ATSE) and the Australian Institute of Company Directors (AICD) and holds a Doctoral Degree in Biochemistry from the University of Adelaide.



**Jennifer Herz** founded Biointelect in 2011 to provide consulting services to the health technology sector. Jennifer has over 20 years commercial, business development and scientific affairs experience in the biopharmaceutical industry and has held a variety of roles with responsibility for Australia, New Zealand and European markets. She was the first Managing Director of Sanofi Pasteur in Australia which was a start-up company and grew significantly over the 6 years of her tenure to be an established major provider of vaccines to the public and private market in Australia, New Zealand and the Pacific Region. From 2003-2007 she served on the Board of Medicines Australia and was the founding Chair of the Medicines Australia Vaccine Industry Group in which she led industry discussions with government related to the new funding arrangements for vaccines on the PBAC. From 2007-2010 Jennifer worked as a consultant for Medimmune/Astra Zeneca responsible for policy and market access in Europe. She was also active in a variety of working groups of both the EFPIA and the IFPMA and responsible for liaison with key opinion leaders and health authorities including European Institutions and the WHO.



**Professor Michael Gold**, MbChB, DCH, FCP, MD, FRACP, is a Paediatric Allergist and Immunologist with conjoint positions in the Discipline of Paediatrics, University of Adelaide and is former Medical Unit Head, of the Department of Allergy and Immunology at the Women's and Children's Health Network. He has a research and clinical interest in the prevention of food allergy and vaccine safety. He was appointed to the World Health Organisation Global Advisory Committee for Vaccine Safety in 2010 and has been an appointed expert advisor to a number of statutory TGA vaccine safety committees since 2006. He has been a Principal Investigator on ARC and NHMRC grants investigating novel methods for vaccine safety surveillance which include data-linkage and use of m-health. His clinical responsibilities include reviewing children who have had adverse events following immunisation within a Specialist Immunisation Service based at the Women's and Children's Hospital. He has performed vaccine safety training for the WHO in multiple low and middle income countries, is a faculty member for the annual "Vaccines for Africa" vaccinology course and has been a contributor or lead author of multiple WHO publications concerning vaccine safety which have covered causality assessment, background rates of adverse reactions and training material for cause-specific adverse events.



**Mathew Palmer**, Msc (Hons), has 23 years' experience in the pharmaceutical industry; 16 of those years being within CROs and the other 7 within pharmaceutical companies. His experience in the clinical research arena extends from phase I to phase IV and includes experience in multiple therapeutic areas. He is also the SA Branch Chair of AusBiotech. Mathew's current role is Director, Business Development at INC Research. Immediately prior to this, his role was Project Director for the Early Phase Development, Asia Pacific Business Unit at INC Research. In this role he was responsible for the oversight of the Project Management team and the delivery of the early phase studies in Asia Pacific for INC Research. Prior to this, he was responsible for the management and coordination of the study start-up group operating in Australia and New Zealand for INC Research. He has also held various project management roles (Project Manager, Senior Project Manager and Associate Projects Director), line management roles including Manager, Regional Monitoring as well as monitoring and site management roles. With his expertise in these areas, coupled with regional experience, Mathew provides valuable insight into the conduct of clinical studies to avoid potential delays.